|
1
|
Khan SA, Thomas HC, Davidson BR and
Tayler-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Katanoda K, Hori M, Matsuda T, Shibata A,
Nishino Y, Hattori M, Soda M, Ioka A, Sobue T and Nishimoto H: An
updated report on the trends in cancer incidence and mortality in
Japan, 1958–2013. Jpn J Clin Oncol. 45:390–401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nakeeb A, Pitt HA, Sohn TA, Coleman J,
Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ and Cameron
JL: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and
distal tumors. Ann Surg. 224:463–475. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dinant S, Gerhards MF, Rauws EA, Busch OR,
Gouma DJ and van Gulik TM: Improved outcome of resection of hilar
cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol. 13:872–880.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
DeOliveira ML, Cunningham SC, Cameron JL,
Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ and Schulick
RD: Cholangiocarcinoma: Thirty-one-year experience with 564
patients at a single institution. Ann Surg. 245:755–762. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seyama Y, Kubota K, Sano K, Noie T,
Takayama T, Kosuge T and Makuuchi M: Long-term outcome of extended
hemihepatectomy for hilar bile duct cancer with no mortality and
high survival rate. Ann Surg. 238:73–83. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Neuhaus P, Jonas S, Settmacher U, Thelen
A, Benckert C, Lopez-Hänninen E and Hintze RE: Surgical management
of proximal bile duct cancer: Extended right lobe resection
increases respectability and radicality. Langenbecks Arch Surg.
388:194–200. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kawasaki S, Imamura H, Kobayashi A, Noike
T, Miwa S and Miyagawa S: Results of surgical resection for
patients with hilar bile duct cancer: Application of extended
hepatectomy after biliary drainage and hemihepatic portal vein
embolization. Ann Surg. 238:84–92. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murakami Y, Uemura K, Sudo T, Hayashidani
Y, Nakamura H, Nakashima A and Sueda T: Gemcitabine-based adjuvant
chemotherapy improves survival after aggressive surgery for hilar
cholangiocarcinoma. J Gastrointest Surg. 13:1470–1479. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hirano S, Kondo S, Tanaka E, Shichinohe T,
Tsuchikawa T, Kato K, Matsumoto J and Kawasaki R: Outcome of
surgical treatment of hilar cholangiocarcinoma: A special reference
to postoperative morbidity and mortality. J Hepatobiliary Pancreat
Sci. 17:455–462. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sakamoto Y, Kosuge T, Shimada K, Sano T,
Ojima H, Yamamoto J, Yamasaki S, Takayama T and Makuuchi M:
Prognostic factors of surgical resection in middle and distal bile
duct cancer: An analysis of 55 patients concerning the significance
of ductal and radial margins. Surgery. 137:396–402. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Murakami Y, Uemura K, Hayashidani Y, Sudo
T, Hashimoto T, Ohge H and Sueda T: Prognostic significance of
lymph node metastasis and surgical margin status for distal
cholangiocarcinoma. J Surg Oncol. 95:207–212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kiriyama M, Ebata T, Aoba T, Kaneoka Y,
Arai T, Shimizu Y and Nagino M: Nagoya Surgical Oncology Group:
Prognostic impact of lymph node metastasis in distal
cholangiocarcinoma. Br J Surg. 102:399–406. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim HJ, Kim CY, Hur YH, Koh YS, Kim JC,
Kim HJ and Cho CK: The prognostic factors for survival after
curative resection of distal cholangiocarcinoma: Perineural
invasion and lymphovascular invasion. Surg Today. 44:1879–1886.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sasaki R, Takahashi M, Funato O, Nitta H,
Murakami M, Kawamura H, Suto T, Kanno S and Saito K: Prognostic
significance of lymph node involvement in middle and distal bile
duct cancer. Surgery. 129:677–683. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoshida T, Matsumoto T, Sasaki A, Morii Y,
Aramaki M and Kitano S: Prognostic factors after
pancreatoduodenectomy with extended lymphadenectomy for distal bile
duct cancer. Arch Surg. 137:69–73. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hong SM, Cho H, Lee OJ and Ro JY: The
number of metastatic lymph nodes in extrahepatic bile duct
carcinoma as a prognostic factor. Am J Surg Pathol. 29:1177–1183.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Murakami Y, Uemura K, Hayashidani Y, Sudo
T, Ohge H and Sueda T: Pancreatoduodenectomy for distal
cholangiocarcinoma: Prognostic impact of lymph node metastasis.
World J Surg. 31:337–344. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kawai M, Tani M, Kobayashi Y, Tsuji T,
Tabuse K, Horiuchi T, Oka M, Yamaguchi K, Sakata Y, Shimomura T and
Yamaue H: The ratio between metastatic and examined lymph nodes is
an independent prognostic factor for patients with resectable
middle and distal bile duct carcinoma. Am J Surg. 199:447–452.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tamnandl D, Kanczicek K, Gruenberger B,
Koelblinger C, Maresch J, Jakesz R and Gruenberger T: Lymph node
ratio after curative surgery for intrahepatic cholangiocarcinoma.
Br J Surg. 96:919–925. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aoba T, Ebata T, Yokoyama Y, Igami T,
Sugawara G, Takahashi Y, Nimura Y and Nagino M: Assessment of nodal
status for perihilar cholangiocarcinoma: Location, number, or ratio
of involved nodes. Ann Surg. 257:718–725. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Murakami Y, Uemura K, Sudo T, Hashimoto Y,
Nakashima A, Kondo N, Sakabe R, Ohge H and Sueda T: Prognostic
factors after surgical resection for intrahepatic, hilar, and
distal cholangiocarcinoma. Ann Surg Oncol. 18:651–658. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kwon HJ, Kim SG, Chun JM, Lee WK and Hwang
YJ: Prognostic factors in patients with middle and distal bile duct
cancers. World J Gastroenterol. 20:6658–6665. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nagahashi M, Shirai Y, Wakai T, Sakata J,
Ajioka Y, Nomura T, Tsuchiya Y and Hatakeyama K: Depth of invasion
determines the postresectional prognosis for patients with T1
extrahepatic cholangiocarcinoma. Cancer. 116:400–405. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kimura N, Toyoki Y, Ishido K, Kudo D,
Yakoshi Y, Tsutsumi S, Miura T, Wakiya T and Hakamada K:
Perioperative blood transfusion as a poor prognostic factor after
aggressive surgical resection for hilar cholangiocarcinoma. J
Gastrointest Surg. 19:866–879. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fernández-Ruiz M, Guerra-Vales JM and
Colina-Ruizdelgado F: Comorbidity negatively influences prognosis
in patients with extrahepatic cholangiocarcinoma. World J
Gastroenterol. 15:5279–5286. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Akahani S, Nangia-Makker P, Inohara H, Kim
HR and Raz A: Galectin-3: A novel antiapoptotic molecule with a
functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res.
57:5272–5276. 1997.PubMed/NCBI
|
|
28
|
Danguy A, Camby I and Kiss R: Galectins
and cancer. Biochem Biophys Acta. 1572:285–293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Davidson PJ, Davis MJ, Patterson RJ,
Ripoche MA, Poirier F and Wang JL: Shuttling of galectin-3 between
the nucleus and cytoplasm. Glycobiology. 12:329–337. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin HM, Pestell RG, Raz A and Kim HR:
Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a
cAMP-responsive element in human breast epithelial cells. Oncogene.
21:8001–8010. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim MK, Sung CO, Do IG, Jeon HK, Song TJ,
Park HS, Lee YY, Kim BG, Lee JW and Bae DS: Overexpression of
galectin-3 and its clinical significance in ovarian carcinoma. Int
J Clin Oncol. 16:352–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Acikalin MF, Etiz D, Gurbuz MK, Ozudogru
E, Canaz F and Colak E: Prognostic significance of galectin-3 and
cyslin D1 expression in undifferentiated nasopharyngeal carcinoma.
Med Oncol. 29:742–749. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brown ER, Doig T, Anderson N, Brenn T,
Doherty V, Xu Y, Bartlett JM, Smyth JF and Melton DW: Association
of galectin-3 expression with melanoma progression and prognosis.
Eur J Cancer. 48:865–874. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang LP, Jiang S, Liu JQ, Miao XY and Yang
ZL: Up-regulation of galectin-3 and sambucus nigra agglutinin
binding site is associated with invasion, metastasis and
poor-progression of the gallbladder adenocarcinoma.
Hepatogastroenterology. 59:2089–2094. 2012.PubMed/NCBI
|
|
35
|
Zhou X, Jing J, Peng J, Mao W, Zheng Y,
Wang D, Wang X, Liu Z and Zhang X: Expression and clinical
significance of galectin-3 in osteosarcoma. Gene. 546:403–407.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang SS, Weng DS, Wang QJ, Pan K, Zhang
YJ, Li YQ, Li JJ, Zhao JJ, He J, Lv L, et al: Galectin-3 is
associated with a poor prognosis in primary hepatocellular
carcinoma. J Transl Med. 12:2732014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shimamura T, Sakamoto M, Ino Y, Shimada K,
Kosuge T, Sato Y, Tanaka K, Sekihara H and Hirohashi S:
Clinicopathological significance of galectin-3 expression in ductal
adenocarcinoma of the pancreas. Clin Cancer Res. 8:2570–2575.
2002.PubMed/NCBI
|
|
38
|
Piantelli M, Iacobelli S, Almadori G,
Iezzi M, Tinari N, Natoli C, Cadoni G, Lauriola L and Ranelletti
FO: Lack of expression of galectin-3 is associated with a poor
outcome in node-negative patients with laryngeal squamous-cell
carcinoma. J Clin Oncol. 20:3850–3856. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Okada K, Shimura T, Suehiro T, Mochiki E
and Kuwano H: Reduced galectin-3 expression is an indicator of
favorable prognosis in gastric cancer. Anticancer Res.
26:1369–1376. 2006.PubMed/NCBI
|
|
40
|
Merseburger AS, Kramer MW, Hennenlotter J,
Serth J, Kruck S, Gracia A, Stenzl A and Kuczyk MA: Loss of
galectin-3 expression correlates with clear cell renal carcinoma
progression and reduced survival. World J Urol. 26:637–642. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yamaki S, Fujii T, Yajima R, Hirakata T,
Yamaguchi S, Fujisawa T, Tsutsumi S, Asao T, Yanagita Y, Iijima M
and Kuwano H: Clinicopathological significance of decreased
galectin-3 expression and the long-term prognosis in patients with
breast cancer. Surg Today. 43:901–905. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shimonishi T, Miyazaki K, Kono N, Sabit H,
Tuneyama K, Harada K, Hirabayashi J, Kasai K and Nakanuma Y:
Expression of endogenous galectin-1 and galectin-3 in intrahepatic
cholangiocarcinoma. Hum Pathol. 32:302–310. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Junking M, Wongkham C, Sripa B,
Sawanyawisuth K, Araki N and Wongkham S: Decreased expression of
galectin-3 is associated with metastatic potential of liver
fluke-associated cholangiocarcinoma. Eur J Cancer. 44:619–626.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wongkham S, Junking M, Wongkham C, Sripa
B, Chur-In S and Araki N: Suppression of galectin-3 expression
enhances apoptosis and chemosensitivity in liver fluke-associated
cholangiocarcinoma. Cancer Sci. 100:2077–2084. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Simpson CD, Anyiwe K and Schimmer AD:
Anoikis resistance and tumor metastasis. Cancer Lett. 272:177–185.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sobin LH, Gospodarowicz MK and Wittekind
C: Union for International Cancer Control (UICC): TNM
classification of malignant tumors. 7th. Wiley-Blackwell; New York:
2010
|
|
47
|
van Domberg R, Hoeks S, Kardys I, Lenzen M
and Boersma E: Tools and techniques-statistics: How many variables
are allowed in the logistic and Cox regression models?
EuroIntervention. 9:1472–1473. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Thijssen VL, Heusschen R, Caers J and
Griffioen AW: Galectin expression in cancer diagnosis and
prognosis: A systematic review. Biochim Biophys Acta. 1855:235–247.
2015.PubMed/NCBI
|
|
49
|
Kobayashi T, Shimura T, Yajima T, Kubo N,
Araki K, Wada W, Tsutsumi S, Suzuki H, Kuwano H and Raz A:
Transient silencing of galectin-3 expression promotes both in vitro
and in vivo drug-induced apoptosis of human pancreatic carcinoma
cells. Clin Exp Metastasis. 28:367–376. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cao Z, Livas T and Kyprianou N: Anoikis
and EMT: Lethal ‘liaisons’ during cancer progression. Crit Rev
Oncog. 21:155–168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kao SH, Wang WL, Chen CY, Chang YL, Wu YY,
Wang YT, Wang SP, Nesvizhskii AI, Chen YJ, Hong TM and Yang PC:
GSK3β controls epithelial-mesenchymal transition and tumor
metastasis by CHIP-mediated degradation of Slug. Oncogene.
33:3172–3182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shimura T, Takenaka Y, Fukumori T,
Tsutsumi S, Okada K, Hogan V, Kuwano H and Raz A: Implication of
galectin-3 in Wnt signaling. Cancer Res. 65:3535–3537. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Song S, Mazurek N, Liu C, Sun Y, Ding QQ,
Liu K, Hung MC and Bresalier RS: Galectin-3 mediates nuclear
β-catenin accumulation and Wnt signaling in human colon cancer
cells by regulation of glycogen synthase kinase-3β activity. Cancer
Res. 69:1343–1349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mendonça DF, Chammas R, Liu FT, Nonogaki
S, Cardoso SV, Loyola AM and de Faria PR: The inactiveform of
glycogen synthase-3beta is associated with the development of
carcinoma in galectin-3 wild-type mice, but not in
galectin-3-deficient mice. Int J Clin Exp Pathol. 5:547–554.
2012.PubMed/NCBI
|
|
55
|
Katsuno Y, Lamouille S and Derynck R:
TGF-β signaling and epithelial-mesenchymal transition in cancer
progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
MacKinnon AC, Gibbons MA, Farnworth SL,
Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N,
Gauldie J and Sethi T: Regulation of transforming growth
factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care
Med. 185:537–546. 2012. View Article : Google Scholar : PubMed/NCBI
|
